|
1
|
Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy.
|
Circ Res
|
2003
|
5.30
|
|
2
|
Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling.
|
J Clin Invest
|
2003
|
2.43
|
|
3
|
Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth.
|
Mol Cell Biol
|
2002
|
2.30
|
|
4
|
Targeted inhibition of p38 mitogen-activated protein kinase antagonizes cardiac injury and cell death following ischemia-reperfusion in vivo.
|
J Biol Chem
|
2004
|
2.24
|
|
5
|
Genetic loss of calcineurin blocks mechanical overload-induced skeletal muscle fiber type switching but not hypertrophy.
|
J Biol Chem
|
2004
|
1.82
|
|
6
|
Altered skeletal muscle phenotypes in calcineurin Aalpha and Abeta gene-targeted mice.
|
Mol Cell Biol
|
2003
|
1.71
|
|
7
|
MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo.
|
Circulation
|
2004
|
1.69
|
|
8
|
APJ acts as a dual receptor in cardiac hypertrophy.
|
Nature
|
2012
|
1.62
|
|
9
|
DUSP6 (MKP3) null mice show enhanced ERK1/2 phosphorylation at baseline and increased myocyte proliferation in the heart affecting disease susceptibility.
|
J Biol Chem
|
2008
|
1.58
|
|
10
|
Extracellular signal-regulated kinase 2 interacts with and is negatively regulated by the LIM-only protein FHL2 in cardiomyocytes.
|
Mol Cell Biol
|
2004
|
1.57
|
|
11
|
PKC alpha regulates the hypertrophic growth of cardiomyocytes through extracellular signal-regulated kinase1/2 (ERK1/2).
|
J Cell Biol
|
2002
|
1.51
|
|
12
|
c-Jun N-terminal kinases (JNK) antagonize cardiac growth through cross-talk with calcineurin-NFAT signaling.
|
EMBO J
|
2003
|
1.42
|
|
13
|
Direct and indirect interactions between calcineurin-NFAT and MEK1-extracellular signal-regulated kinase 1/2 signaling pathways regulate cardiac gene expression and cellular growth.
|
Mol Cell Biol
|
2005
|
1.34
|
|
14
|
Unrestrained p38 MAPK activation in Dusp1/4 double-null mice induces cardiomyopathy.
|
Circ Res
|
2012
|
0.99
|
|
15
|
Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction.
|
Eur J Heart Fail
|
2013
|
0.82
|